Influence of transcriptional variants on metastasis

References

• Valastyan S, Weinberg RA. Tumor Metastasis : molecular Insights and Evolving Paradigms. Cell. 2011;147(2):275–292.
   PubMed Web of Science ®Google Scholar
• Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015;5(5):402–418.
   PubMed Web of Science ®Google Scholar
• Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274–284.
   PubMed Web of Science ®Google Scholar
• Steeg PS. Targeting metastasis. Nat Rev Cancer. 2016;16(4):201–218.
   PubMed Web of Science ®Google Scholar
• Lee SC-W, Abdel-Wahab O. Therapeutic targeting of splicing in cancer. Nat Med. 2016;22(9):976–986.
   PubMed Web of Science ®Google Scholar
• Pal S, Gupta R, Davuluri RV. Alternative transcription and alternative splicing in cancer. Pharmacol Ther. 2012;136(3):283–294.
   PubMed Web of Science ®Google Scholar
• Corkery DP, Holly AC, Lahsaee S, et al. Connecting the speckles: splicing kinases and their role in tumorigenesis and treatment response. Nucleus. 2015;6(4):279–288.
   PubMed Web of Science ®Google Scholar
• Silipo M, Gautrey H, Tyson-Capper A. Deregulation of splicing factors and breast cancer development. J Mol Cell Biol. 2015;7(5):388–401.
   PubMed Web of Science ®Google Scholar
• Lu Z, Huang Q, Park JW, et al. Transcriptome-wide Landscape of Pre-mRNA Alternative Splicing Associated with Metastatic Colonization. Mol Cancer Res. 2015;13(2):305–318.
   PubMed Web of Science ®Google Scholar
• Oltean S, Bates DO. Hallmarks of alternative splicing in cancer. Oncogene. 2013;33(46):5311–5318.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu J, Huang BO, et al. Mechanism of alternative splicing and its regulation. Biomed reports. 2015;3(2):152–158.
   PubMed Web of Science ®Google Scholar
• Sibley CR, Blazquez L, Ule J. Lessons from non-canonical splicing. Nat Rev Genet. 2016;17(7):407–421.
   PubMed Web of Science ®Google Scholar
• Jacob AG, Smith CWJ. Intron retention as a component of regulated gene expression programs. Hum Genet. 2017;136(9):1043–1057.
   PubMed Web of Science ®Google Scholar
• Kovacs E, Tompa P, Liliom K, et al. Dual coding in alternative reading frames correlates with intrinsic protein disorder. Proc Natl Acad Sci USA. 2010;107(12):5429–5434.
   Google Scholar
• Sveen A, Kilpinen S, Ruusulehto A, et al. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene. 2015;35(19):2413–2427.
   PubMed Web of Science ®Google Scholar
• Scotti MM, Swanson MS. RNA mis-splicing in disease. Nat Rev Genet. 2016;17(1):19–32.
   PubMed Web of Science ®Google Scholar
• Paronetto MP, Passacantilli I, Sette C. Alternative splicing and cell survival: from tissue homeostasis to disease. Cell Death Differ. 2016;23(12):1919–1929.
   PubMed Web of Science ®Google Scholar
• Matera AG, Wang Z. A day in the life of the spliceosome. Nat Rev Mol Cell Biol. 2014;15(2):108–121.
   PubMed Web of Science ®Google Scholar
• Merkhofer EC, Hu P, Johnson TL. Introduction to Cotranscriptional RNA Splicing. Methods Mol Biol. 2014;1126:83–96.
   PubMedGoogle Scholar
• Papasaikas P, Valcárcel J. The Spliceosome: the Ultimate RNA Chaperone and Sculptor. Trends Biochem Sci. 2016;41(1):33–45.
   PubMed Web of Science ®Google Scholar
• Kornblihtt AR, Schor IE, Alló M, et al. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol. 2013;14(3):153–165.
   PubMed Web of Science ®Google Scholar
• Kelemen O, Convertini P, Zhang Z, et al. Function of alternative splicing. Gene. 2013;514(1):1–30.
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu D, Yin B, et al. High expression of PTBP1 promote invasion of colorectal cancer by alternative splicing of cortactin. Oncotarget. 2017;8(22):36185–36202.
   PubMedGoogle Scholar
• Dvinge H, Kim E, Abdel-Wahab O, et al. RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer. 2016;16(7):413–430.
   PubMed Web of Science ®Google Scholar
• Iannone C, Valcárcel J. Chromatin’s thread to alternative splicing regulation. Chromosoma. 2013;122(6):465–474.
   PubMed Web of Science ®Google Scholar
• Simon JM, Hacker KE, Singh D, et al. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res. 2014;24(2):241–250.
   PubMed Web of Science ®Google Scholar
• Jung H, Lee D, Lee J, et al. Intron retention is a widespread mechanism of tumor-suppressor inactivation. Nat Genet. 2015;47(11):1242–1248.
   PubMed Web of Science ®Google Scholar
• Marquez Y, Höpfler M, Ayatollahi Z, et al. Unmasking alternative splicing inside protein-coding exons defines exitrons and their role in proteome plasticity. Genome Res. 2015;25(7):995–1007.
   PubMed Web of Science ®Google Scholar
• Staiger D, Simpson GG. Enter exitrons. Genome Biol. 2015;16(1):136.
   PubMedGoogle Scholar
• Jiang WG, Sanders AJ, Katoh M, et al. Tissue invasion and metastasis: molecular, biological and clinical perspectives. Semin Cancer Biol. 2015;35:S244–75.
   PubMed Web of Science ®Google Scholar
• Buchheit CL, Weigel KJ, Schafer ZT. Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer. 2014;14(9):632–641.
   PubMed Web of Science ®Google Scholar
• Van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res - Rev Mutat Res. 2011;728(1–2):23–34.
   PubMed Web of Science ®Google Scholar
• Chaffer CL, San Juan BP, Lim E, et al. EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 2016;35(4):645–654.
   PubMed Web of Science ®Google Scholar
• Warzecha CC, Carstens RP. Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Semin Cancer Biol. 2012;22(5–6):417–427.
   PubMed Web of Science ®Google Scholar
• Takano S, Reichert M, Bakir B, et al. Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. Genes Dev. 2016;30(2):233–247.
   PubMed Web of Science ®Google Scholar
• Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529(7586):298–306.
   PubMed Web of Science ®Google Scholar
• Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci. 2014;111(30):E3053–61.
   PubMed Web of Science ®Google Scholar
• Senft D, Ronai ZA. Adaptive Stress Responses During Tumor Metastasis and Dormancy. Trends in Cancer. 2016;2(8):429–442.
   Web of Science ®Google Scholar
• Lorusso G, Rüegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol. 2012;22(3):226–233.
   PubMed Web of Science ®Google Scholar
• Abou Faycal C, Gazzeri S, Eymin B. RNA splicing, cell signaling, and response to therapies. Curr Opin Oncol. 2016;28(1):58–64.
   PubMed Web of Science ®Google Scholar
• Anczuków O, Krainer AR. Splicing-factor alterations in cancers. RNA. 2016;22(9):1285–1301.
   PubMed Web of Science ®Google Scholar
• Luz FAC, Brígido PC, Moraes AS, et al. Aberrant Splicing in Cancer: mediators of Malignant Progression through an Imperfect Splice Program Shift. Oncology. 2016.
   PubMed Web of Science ®Google Scholar
• Seidel B, Braeg S, Adler G, et al. E- and N-cadherin differ with respect to their associated p120ctn isoforms and their ability to suppress invasive growth in pancreatic cancer cells. Oncogene. 2004;23(32):5532–5542.
   PubMed Web of Science ®Google Scholar
• Sharma S, Liao W, Zhou X, et al. Exon 11 skipping of E-cadherin RNA downregulates its expression in head and neck cancer cells. Mol Cancer Ther. 2011;10(9):1751–1759.
   PubMed Web of Science ®Google Scholar
• Li X-W, Shi B-Y, Yang Q-L, et al. Epigenetic regulation of CDH1 exon 8 alternative splicing in gastric cancer. BMC Cancer. 2015;15(1):954.
   PubMedGoogle Scholar
• Yang CC, He P, Liu Y, et al. Down-regulation of CEACAM1 in breast cancer. Acta Biochim Biophys Sin (Shanghai). 2015;47(10):788–794.
   PubMed Web of Science ®Google Scholar
• Dery KJ, Gaur S, Gencheva M, et al. Mechanistic control of carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) splice isoforms by the heterogeneous nuclear ribonuclear proteins hnRNP L, hnRNP A1, and hnRNP M. J Biol Chem. 2011;286(18):16039–16051.
   PubMed Web of Science ®Google Scholar
• Dankner M, Gray-Owen SD, Huang YH, et al. CEACAM1 as a multi-purpose target for cancer immunotherapy. Oncoimmunology. 2017;6(7):1–16.
   Web of Science ®Google Scholar
• Ieda J, Yokoyama S, Tamura K, et al. Re-expression of CEACAM1 long cytoplasmic domain isoform is associated with invasion and migration of colorectal cancer. Int J Cancer. 2011;129(6):1351–1361.
   PubMed Web of Science ®Google Scholar
• Kirshner J, Chen C-J, Liu P, et al. CEACAM1-4S, a cell-cell adhesion molecule, mediates apoptosis and reverts mammary carcinoma cells to a normal morphogenic phenotype in a 3D culture. Proc Natl Acad Sci U S A. 2003;100(2):521–526.
   PubMed Web of Science ®Google Scholar
• Senbanjo LT, Chellaiah MA. CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells. Front cell Dev Biol. 2017;5:18.
   PubMed Web of Science ®Google Scholar
• Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4(1):33–45.
   PubMed Web of Science ®Google Scholar
• Birzele F, Voss E, Nopora A, et al. CD44 Isoform status predicts response to treatment with Anti-CD44 antibody in cancer patients. Clin Cancer Res. 2015;21(12):2753–2762.
   PubMed Web of Science ®Google Scholar
• Brown RL, Reinke LM, Damerow MS, et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 2011;121(3):1064–1074.
   PubMed Web of Science ®Google Scholar
• Zhao P, Xu Y, Wei Y, et al. The CD44s splice isoform is a central mediator for invadopodia activity. J Cell Sci. 2016;129(7):1355–1365.
   PubMed Web of Science ®Google Scholar
• Zhao S, Chen C, Chang K, et al. CD44 expression level and isoform contributes to pancreatic cancer cell plasticity, invasiveness, and response to therapy. Clin Cancer Res. 2016;22(22):5592–5604.
   PubMed Web of Science ®Google Scholar
• Prochazka L, Tesarik R, Turanek J. Regulation of alternative splicing of CD44 in cancer. Cell Signal. 2014;26(10):2234–2239.
   PubMed Web of Science ®Google Scholar
• Warzecha CC, Shen S, Xing Y, et al. The epithelial splicing factors ESRP1 and ESRP2 positively and negatively negulate diverse types of alternative splicing events. RNA Biol. 2009;6(5):546.
   PubMed Web of Science ®Google Scholar
• Tripathi V, Sixt KM, Gao S, et al. Direct Regulation of Alternative Splicing by SMAD3 through PCBP1 Is Essential to the Tumor-Promoting Role of TGF-β. Mol Cell. 2016;64(5):1010.
   PubMed Web of Science ®Google Scholar
• Xu Y, Gao XD, Lee JH, et al. Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing. Genes Dev. 2014;28(11):1191–1203.
   PubMed Web of Science ®Google Scholar
• Hu J, Li G, Zhang P, et al. A CD44v+ subpopulation subpopulation of breast cancer stem-like cells with enhanced lung metastasis capacity. Cell Death Dis. 2017;8(3):e2679.
   PubMedGoogle Scholar
• Weber GF, Ashkar S, Glimcher MJ, et al. Receptor-Ligand Interaction Between CD44 and Osteopontin (Eta-1). Science (80-). 1996;271(5248):509–512.
   Web of Science ®Google Scholar
• Todaro M, Gaggianesi M, Catalano V, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014;14(3):342–356.
   PubMed Web of Science ®Google Scholar
• Tremmel M, Matzke A, Albrecht I, et al. A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood. 2009;114(25):5236–5244.
   PubMed Web of Science ®Google Scholar
• Loh TJ, Moon H, Jang HN, et al. SR proteins regulate V 6 exon splicing of CD44 pre-mRNA. BMB Rep. 2016;49(11):612–616.
   PubMed Web of Science ®Google Scholar
• Hernandez JR, Kim JJ, Verdone JE, et al. Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts. Med Oncol. 2015;32(5):159.
   PubMed Web of Science ®Google Scholar
• Sakuma K, Sasaki E, Kimura K, et al. HNRNPLL, a newly identified colorectal cancer metastasis suppressor, modulates alternative splicing of CD44 during epithelial-mesenchymal transition. Gut. 2018;67(6):1103–1111.
   Web of Science ®Google Scholar
• Balsamo M, Mondal C, Carmona G, et al. The alternatively-included 11a sequence modifies the effects of Mena on actin cytoskeletal organization and cell behavior. Sci Rep. 2016;6:35298.
   PubMedGoogle Scholar
• Oudin MJ, Hughes SK, Rohani N, et al. Characterization of the expression of the pro-metastatic MenaINV isoform during breast tumor progression. Clin Exp Metastasis. 2016;33(3):249–261.
   PubMed Web of Science ®Google Scholar
• Melchionnaa R, Iapiccaa P, Di MF, et al. The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome. Oncoimmunology. 2016;5(12):e1221556.
   PubMed Web of Science ®Google Scholar
• Bonomi S, Gallo S, Catillo M, et al. Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy. Int J Cell Biol. 2013;2013:962038.
   PubMedGoogle Scholar
• Trono P, Di Modugno F, Nisticò P. hMENA 11a, a hMENA isoform sending survival signals. Mol Cell Oncol. 2016;3(2):e1083648.
   PubMed Web of Science ®Google Scholar
• Roussos ET, Goswami S, Balsamo M, et al. Mena invasive (MenaINV) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEM. Clin Exp Metastasis. 2011;28(6):515–527.
   PubMed Web of Science ®Google Scholar
• Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer. 2011;11(8):573–587.
   PubMed Web of Science ®Google Scholar
• Oktay MH, Jones JG. TMEM: A novel breast cancer dissemination marker for the assessment of metastatic risk. Biomark Med. 2015;9(2):81–84.
   PubMed Web of Science ®Google Scholar
• Pignatelli J, Goswami S, Jones JG, et al. Invasive breast carcinoma cells from patients exhibit MenaINV-and macrophage-dependent transendothelial migration. Sci Signal. 2014;7(353):ra112.
   PubMed Web of Science ®Google Scholar
• Weidmann MD, Surve CR, Eddy RJ, et al. MenaINV dysregulates cortactin phosphorylation to promote invadopodium maturation. Sci Rep. 2016;6(1):36142.
   PubMedGoogle Scholar
• Fiegen D, Haeusler L-C, Blumenstein L, et al. Alternative Splicing of Rac1 Generates Rac1b, a Self-activating GTPase. J Biol Chem. 2004;279(6):4743–4749.
   PubMed Web of Science ®Google Scholar
• Singh A, Karnoub AE, Palmby TR, et al. Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene. 2004;23(58):9369–9380.
   PubMed Web of Science ®Google Scholar
• Faria M, Capinha L, Simões-Pereira J, et al. Extending the Impact of RAC1b Overexpression to Follicular Thyroid Carcinomas. Int J Endocrinol. 2016;2016:1–7.
   Google Scholar
• Gonçalves V, Henriques A, Pereira J, et al. Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells. RNA. 2014;20(4):474–482.
   PubMed Web of Science ®Google Scholar
• Pelisch F, Khauv D, Risso G, et al. Involvement of hnRNP A1 in the matrix metalloprotease-3-dependent regulation of Rac1 pre-mRNA splicing. J Cell Biochem. 2012;113(7):2319–2329.
   PubMed Web of Science ®Google Scholar
• Wang F, Fu X, Chen P, et al. SPSB1-mediated HnRNP A1 ubiquitylation regulates alternative splicing and cell migration in EGF signaling. Cell Res. 2017;27(4):540–558.
   PubMed Web of Science ®Google Scholar
• Faria M, Matos P, Pereira T, et al. RAC1b overexpression stimulates proliferation and NF-kB-mediated anti-apoptotic signaling in thyroid cancer cells. PLoS One. 2017;12(2):e0172689.
   PubMed Web of Science ®Google Scholar
• Weaver AM. Cortactin in tumor invasiveness. Cancer Lett. 2008;265(2):157–166.
   PubMed Web of Science ®Google Scholar
• Head JA, Jiang D, Li M, et al. Cortactin Tyrosine Phosphorylation Requires Rac1 Activity and Association with the Cortical Actin Cytoskeleton. Mol Biol Cel. 2003;14(8):3216–3229.
   PubMed Web of Science ®Google Scholar
• Katsube T, Togashi S, Hashimoto N, et al. Filamentous actin binding ability of cortactin isoforms is responsible for their cell-cell junctional localization in epithelial cells. Arch Biochem Biophys. 2004;427(1):79–90.
   PubMed Web of Science ®Google Scholar
• Gattazzo C, Martini V, Frezzato F, et al. Cortactin, another player in the Lyn signaling pathway, is over-expressed and alternatively spliced in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Haematologica. 2014;99(6):1069–1077.
   PubMed Web of Science ®Google Scholar
• Johnson RM, Vu NT, Griffin BP, et al. The alternative splicing of cytoplasmic polyadenylation element binding protein 2 drives anoikis resistance and the metastasis of triple negative breast cancer. J Biol Chem. 2015;290(42):25717–25727.
   PubMed Web of Science ®Google Scholar
• Upheber S, Karle A, Miller J, et al. Alternative splicing of KAI1 abrogates its tumor-suppressive effects on integrin αvβ3-mediated ovarian cancer biology. Cell Signal. 2015;27(3):652–662.
   PubMed Web of Science ®Google Scholar
• Lee JH, Seo Y, Park SR, et al. Expression of a Splice Variant of KAI1, a Tumor Metastasis Suppressor Gene, Influences Tumor Invasion and Progression Expression of a Splice Variant of KAI1, a Tumor Metastasis Suppressor Gene, Influences Tumor Invasion and Progression. Group. 2003;63(21):7247–7255.
   Google Scholar
• Miranti CK. Controlling cell surface dynamics and signaling: how CD82/KAI1 suppresses metastasis. Cell Signal. 2009;21(2):196–211.
   PubMed Web of Science ®Google Scholar
• Yang JM, O’Neill P, Jin W, et al. Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of Bim. J Biol Chem. 2006;281(14):9719–9727.
   PubMed Web of Science ®Google Scholar
• Liao C-G, Kong L-M, Song F, et al. Characterization of basigin isoforms and the inhibitory function of basigin-3 in human hepatocellular carcinoma proliferation and invasion. Mol Cell Biol. 2011;31(13):2591–2604.
   PubMed Web of Science ®Google Scholar
• Yao H-P, Zhou Y-Q, Zhang R, et al. MSP–RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer. 2013;13(7):466–481.
   PubMed Web of Science ®Google Scholar
• Moxley KM, Wang L, Welm AL, et al. Short-form Ron is a novel determinant of ovarian cancer initiation and progression. Genes Cancer. 2016;7(5–6):169–181.
   PubMedGoogle Scholar
• Lu Y, Yao HP, Wang MH. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett. 2007;257(2):157–164.
   PubMed Web of Science ®Google Scholar
• Mayer S, Hirschfeld M, Jaeger M, et al. RON alternative splicing regulation in primary ovarian cancer. Oncol Rep. 2015;34(1):423–430.
   PubMed Web of Science ®Google Scholar
• LeFave CV, Squatrito M, Vorlova S, et al. Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J. 2011;30(19):4084–4097.
   PubMed Web of Science ®Google Scholar
• Golan-Gerstl R, Cohen M, Shilo A, et al. Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res. 2011;71(13):4464–4472.
   PubMed Web of Science ®Google Scholar
• Pagliarini V, Naro C, Sette C. Splicing Regulation: A Molecular Device to Enhance Cancer Cell Adaptation. Biomed Res Int. 2015;2015:543067.
   PubMedGoogle Scholar
• Bharadwaj S, Thanawala R, Bon G, et al. Resensitization of breast cancer cells to anoikis by tropomyosin-1: role of Rho kinase-dependent cytoskeleton and adhesion. Oncogene. 2005;24(56):8291–8303.
   PubMed Web of Science ®Google Scholar
• Gunning P, Neill GO, Hardeman E. Tropomyosin-Based Regulation of the Actin Cytoskeleton in Time and Space. Physiol Rev. 2008;88(1):1–35.
   PubMed Web of Science ®Google Scholar
• Desouza M, Gunning PW, Stehn JR. The actin cytoskeleton as a sensor and mediator of apoptosis. Bioarchitecture. 2012;2(3):75–87.
   PubMedGoogle Scholar
• Pan H, Gu L, Liu B, et al. Tropomyosin-1 acts as a potential tumor suppressor in human oral squamous cell carcinoma. PLoS One. 2017;12(2):e0168900.
   PubMed Web of Science ®Google Scholar
• Dube S, Yalamanchili S, Lachant J, et al. Expression of Tropomyosin 1 Gene Isoforms in Human Breast Cancer Cell Lines. Int J Breast Cancer. 2015;2015:859427.
   PubMedGoogle Scholar
• Yang J, Zeng Z, Peng Y, et al. IL-7 splicing variant IL-7δ5 induces EMT and metastasis of human breast cancer cell lines MCF-7 and BT-20 through activation of PI3K/Akt pathway. Histochem Cell Biol. 2014;142(4):401–410.
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572.
   PubMed Web of Science ®Google Scholar
• Wu Q, Dhir R, Wells A. Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer. 2012;11:3.
   PubMed Web of Science ®Google Scholar
• Li Y, Reader JC, Ma X, et al. Divergent roles of CXCR3 isoforms in promoting cancer stem-like cell survival and metastasis. Breast Cancer Res Treat. 2015;149(2):403–415.
   PubMed Web of Science ®Google Scholar
• Ding Q, Xia Y, Ding S, et al. An alternatively spliced variant of CXCR3 mediates the metastasis of CD133 + liver cancer cells induced by CXCL9. Oncotarget. 2016;7(12):14405–14414.
   PubMedGoogle Scholar
• Allami RH, Graf C, Martchenko K, et al. Analysis of the expression of SDF-1 splicing variants in human colorectal cancer and normal mucosa tissues. Oncol Lett. 2016;11(3):1873–1878.
   PubMed Web of Science ®Google Scholar
• Woo IS, Hong SH, Byun JH, et al. Circulating stromal cell derived factor-1α (SDF-1α) is predictive of distant metastasis in gastric carcinoma. Cancer Invest. 2008;26(3):256–261.
   PubMed Web of Science ®Google Scholar
• Seguin L, Desgrosellier JS, Weis SM, et al. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015;25(4):234–240.
   PubMed Web of Science ®Google Scholar
• Groulx J-F, Giroux V, Beauséjour M, et al. Integrin α6A splice variant regulates proliferation and the Wnt/β-catenin pathway in human colorectal cancer cells. Carcinogenesis. 2014;35(6):1217–1227.
   PubMed Web of Science ®Google Scholar
• Goel HL, Gritsko T, Pursell B, et al. Regulated splicing of the α6 integrin cytoplasmic domain determines the fate of breast cancer stem cells. CellReports. 2014;7(3):747–761.
   Google Scholar
• Jiang P, Li Z, Tian F, et al. Fyn/heterogeneous nuclear ribonucleoprotein E1 signaling regulates pancreatic cancer metastasis by affecting the alternative splicing of integrin β1. Int J Oncol. 2017;51(1):169–183.
   PubMed Web of Science ®Google Scholar
• Yoon H, Dehart JP, Murphy JM, et al. Understanding the Roles of FAK in Cancer: inhibitors, Genetic Models, and New Insights. J Histochem Cytochem. 2015;63(2):114–128.
   PubMed Web of Science ®Google Scholar
• Yao L, Li K, Peng W, et al. An aberrant spliced transcript of focal adhesion kinase is exclusively expressed in human breast cancer. J Transl Med. 2014;12(1):136.
   PubMedGoogle Scholar
• Despeaux M, Chicanne G, Rouer E, et al. Focal adhesion kinase splice variants maintain primitive acute myeloid leukemia cells through altered Wnt signaling. Stem Cells. 2012;30(8):1597–1610.
   PubMed Web of Science ®Google Scholar
• Hao C, Cui Y, Owen S, et al. Human osteopontin: potential clinical applications in cancer (Review). Int J Mol Med. 2017;39(6):1327–1337.
   PubMed Web of Science ®Google Scholar
• Lin J, Myers AL, Wang Z, et al. Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget. 2015;6(26):22239–22257.
   PubMedGoogle Scholar
• Shen H, Weber GF. The osteopontin-c splice junction is important for anchorage-independent growth. Mol Carcinog. 2014;53(6):480–487.
   PubMed Web of Science ®Google Scholar
• Hao C, Cui Y, Hu M, et al. OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and its Effects on the Bone Metastatic Abilities of Lung Cancer Cells In Vitro. Anticancer Res. 2017;37(5):2245–2254.
   PubMed Web of Science ®Google Scholar
• Tang X, Li J, Yu B, et al. Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer. Int J Biol Sci. 2013;9(1):55–66.
   PubMed Web of Science ®Google Scholar
• Bueno Ferreira L, Tavares C, Pestana A, et al. Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior. Oncotarget. 2016;7(32):52003–52016.
   PubMedGoogle Scholar
• Sun J, Feng A, Chen S, et al. Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-β1. Cell Mol Immunol. 2013;10(2):176–182.
   PubMed Web of Science ®Google Scholar
• White ES, Muro AF. Fibronectin splice variants: understanding their multiple roles in health and disease using engineered mouse models. IUBMB Life. 2011;63(7):538–546.
   PubMed Web of Science ®Google Scholar
• White E, Baralle F, Muro A. New insights into form and function of fibronectin splice variants. J Pathol. 2008;216(1):1–14.
   PubMed Web of Science ®Google Scholar
• Frey K, Fiechter M, Schwager K, et al. Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. Exp Dermatol. 2011;20(8):685–688.
   PubMed Web of Science ®Google Scholar
• Ou JJ, Wu F, Liang HJ. Colorectal tumor derived fibronectin alternatively spliced EDA domain exserts lymphangiogenic effect on human lymphatic endothelial cells. Cancer Biol Ther. 2010;9(3):186–191.
   PubMed Web of Science ®Google Scholar
• Bordeleau F, Califano JP, Abril YLN, et al. Tissue stiffness regulates serine/arginine-rich protein-mediated splicing of the extra domain B-fibronectin isoform in tumors. Proc Natl Acad Sci. 2015;112(27):8314–8319.
   PubMed Web of Science ®Google Scholar
• Liguori M, Solinas G, Germano G, et al. Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma. Cancers (Basel). 2011;3(4):3740–3761.
   PubMedGoogle Scholar
• Richter P, Junker K, Franz M, et al. IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC). J Cancer Res Clin Oncol. 2008;134(10):1059–1065.
   PubMed Web of Science ®Google Scholar
• Solinas G, Schiarea S, Liguori M, et al. Tumor-Conditioned Macrophages Secrete Migration-Stimulating Factor: A New Marker for M2-Polarization, Influencing Tumor Cell Motility. J Immunol. 2010;185(1):642–652.
   PubMed Web of Science ®Google Scholar
• Perrier S, Woolston A-M, Purdie CA, Kazmi S, Preece PE, Davey KJ, Schor SL, Schor AM. Migration Stimulating Factor (MSF). A Novel Biomarker of Breast Cancer Progression. Transl Med. 2012;S1:003.
   Google Scholar
• Olivos DJ, Mayo LD. Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness. Int J Mol Sci. 2016;17(12):E1982.
   PubMed Web of Science ®Google Scholar
• Pflaum J, Schlosser S, Müller M. p53 Family and Cellular Stress Responses in Cancer. Front Oncol. 2014;4:285.
   PubMedGoogle Scholar
• Gadea G, Arsic N, Fernandes K, et al. TP53 drives invasion through expression of its Δ133p53β variant. Elife. 2016;5:e14734.
   PubMed Web of Science ®Google Scholar
• Arsic N, Gadea G, Lagerqvist EL, et al. The p53 isoform Δ133p53β promotes cancer stem cell potential. Stem Cell Reports. 2015;4(4):531–540.
   PubMed Web of Science ®Google Scholar
• Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage : complexity in action. Trends Cell Biol. 2004;14(11):628–638.
   PubMed Web of Science ®Google Scholar
• Stanley ER, Berg KL, Einstein DB, et al. Biology and Action of Colony – stimulating Factor-1. Mol Reprod Dev. 1997;46(1):4–10.
   PubMed Web of Science ®Google Scholar
• Ladner MB, Martin GA, Noble JA, et al. Human CSF-1: gene structure and alternative splicing of mRNA precursors. EMBO J. 1987;6(9):2693–2698.
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang Y. Tumor-associated macrophages : from basic research to clinical application. J Hematol Oncol. 2017;10(1):58.
   PubMed Web of Science ®Google Scholar
• Liao J, Feng W, Wang R, et al. Diverse in vivo effects of soluble and membrane-bound M-CSF on tumor-associated macrophages in lymphoma xenograft model. Oncotarget. 2016;7(2):1354–1366.
   PubMedGoogle Scholar
• Norris RA, Kern MJ. The Identification of Prx1 Transcription Regulatory Domains Provides a Mechanism for Unequal Compensation by the Prx1 and Prx2 Loci. J Biol Chem. 2001;276(29):26829–26837.
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhang P, Zhou M, et al. 4 decletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer. Carcinogenesis. 2013;34(11):2639–2646.
   PubMed Web of Science ®Google Scholar
• Greenall SA, Johns TG. EGFRvIII: the promiscuous mutation. Cell Death Discov. 2016;2:16049.
   PubMedGoogle Scholar
• Guillaudeau A, Durand K, Bessette B, et al. Egfr soluble isoforms and their transcripts are expressed in meningiomas. PLoS One. 2012;7(5):e37204.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou M, Shi B, et al. Identification of an Exon 4-Deletion Variant of Epidermal Growth Factor Receptor with Increased Metastasis-Promoting Capacity. Neoplasia. 2011;13(5):461–471.
   PubMed Web of Science ®Google Scholar
• Wang H, Shi B, Zhang Q, et al. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation. FASEB J. 2012;26(1):73–80.
   PubMed Web of Science ®Google Scholar
• Manrique I, Nguewa P, Bleau AM, et al. The inhibitor of differentiation isoform Id1b, generated by alternative splicing, maintains cell quiescence and confers self-renewal and cancer stem cell-like properties. Cancer Lett. 2015;356(2 Pt B):899–909.
   PubMed Web of Science ®Google Scholar
• Giancotti FG. Mechanisms Governing Metastatic Dormancy and Reactivation. Cell. 2013;155(4):750–764.
   PubMed Web of Science ®Google Scholar
• Chen W, Dong J, Haiech J, et al. Cancer stem cell quiescence and plasticity as major challenges in cancer therapy. Stem Cells Int. 2016;2016:1740936.
   PubMed Web of Science ®Google Scholar
• Hatakeyama K, Yamakawa Y, Fukuda Y, et al. A novel splice variant of XIAP-associated factor 1 (XAF1) is expressed in peripheral blood containing gastric cancer-derived circulating tumor cells. Gastric Cancer. 2015;18(4):751–761.
   PubMed Web of Science ®Google Scholar
• Li Z, Mou H, Wang T, et al. A non-secretory form of FAM3B promotes invasion and metastasis of human colon cancer cells by upregulating Slug expression. Cancer Lett. 2013;328(2):278–284.
   PubMed Web of Science ®Google Scholar
• Kong L, Yao L, Lu N, et al. Interaction of KLF6 and Sp1 regulates basigin-2 expression mediated proliferation, invasion and metastasis in hepatocellular carcinoma. Oncotarget. 2016;7(19):27975–27987.
   PubMedGoogle Scholar
• Narla G, Difeo A, Yao S, et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res. 2005;65(13):5761–5768.
   PubMed Web of Science ®Google Scholar
• Hatami R, Sieuwerts AM, Izadmehr S, et al. KLF6-SV1 Drives Breast Cancer Metastasis and Is Associated with Poor Survival. Sci Transl Med. 2013;5(169):169ra12.
   PubMed Web of Science ®Google Scholar
• DiFeo A, Martignetti JA, Narla G. The role of KLF6 and its splice variants in cancer therapy. Drug Resist Updat. 2009;12(1–2):1–7.
   PubMed Web of Science ®Google Scholar
• Lu H, Liu J, Liu S, et al. Exo70 isoform switching upon epithelial-mesenchymal transition mediates cancer cell invasion. Dev Cell. 2013;27(5):560–573.
   PubMed Web of Science ®Google Scholar
• Xiao L, Zheng K, Lv X, et al. Exo70 is an independent prognostic factor in colon cancer. Sci Rep. 2017;7(1):5039.
   PubMedGoogle Scholar
• Luo Z, Cheng S, Shi J, et al. A splicing variant of Merlin promotes metastasis in hepatocellular carcinoma. Nat Commun. 2015;6:8457.
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Zuntini M, Manara MC, et al. CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene. 2007;26(46):6604–6618.
   PubMed Web of Science ®Google Scholar
• Byun HJ, Hong IK, Kim E, et al. A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways. J Biol Chem. 2006;281(46):34833–34847.
   PubMed Web of Science ®Google Scholar
• Da Silva MR, Moreira GA, Gonçalves Da Silva RA, et al. Splicing regulators and their roles in cancer biology and therapy. Biomed Res Int. 2015;2015:150514.
   PubMed Web of Science ®Google Scholar
• Zhang ZF, Pal S, Bi Y, et al. Isoform level expression profiles provide better cancer signatures than gene level expression profiles. Genome Med. 2013;5(4):33.
   PubMedGoogle Scholar
• Le K-Q, Prabhakar BS, Hong W-J, et al. Alternative splicing as a biomarker and potential target for drug discovery. Acta Pharmacol Sin. 2015;36(10):1212–1218.
   PubMed Web of Science ®Google Scholar
• Ren P, Li M, Li T, et al. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma. Curr Pharm Des. 2017;23(14):2113–2116.
   PubMed Web of Science ®Google Scholar
• Hong DS, Kurzrock R, Naing A, et al. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest New Drugs. 2014;32(3):436–444.
   PubMed Web of Science ®Google Scholar
• Koh CM, Bezzi M, Low DHP, et al. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature. 2015;523(7558):96–100.
   PubMed Web of Science ®Google Scholar
• Hsu TY, Simon LM, Neill NJ, et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. 2015;525(7569):384–388.
   PubMed Web of Science ®Google Scholar
• Jordaan G, Liao W, Sharma S. E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors. BMC Cancer. 2013;13(1):88.
   PubMedGoogle Scholar
• Yan Y, Zuo X, Wei D. Concise Review: emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target. Stem Cells Transl Med. 2015;4(9):1033–1043.
   PubMed Web of Science ®Google Scholar
• Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11(4):254–267.
   PubMed Web of Science ®Google Scholar
• Misra S, Hascall VC, De Giovanni C, et al. Delivery of CD44 shRNA/nanoparticles within cancer cells. Perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+mice. J Biol Chem. 2009;284(18):12432–12446.
   PubMed Web of Science ®Google Scholar
• Orian-Rousseau V, Ponta H. Perspectives of CD44 targeting therapies. Arch Toxicol. 2015;89(1):3–14.
   PubMed Web of Science ®Google Scholar
• Ying L, Li G, Wei -S-S, et al. Sanguinarine inhibits Rac1b-rendered cell survival enhancement by promoting apoptosis and blocking proliferation. Nat Publ Gr. 2014;36(10):229–240.
   Google Scholar
• Matos P, Kotelevets L, Jordan P, et al. Ibuprofen Inhibits Colitis-Induced Overexpression of Tumor Related Rac1b. Neoplasia. 2013;15(1):102–111.
   PubMed Web of Science ®Google Scholar
• Bieniasz M, Radhakrishnan P, Faham N, et al. Pre-clinical efficacy of Ron kinase inhibitors alone and in combination with PI3K inhibitors for treatment of sfRon- expressing breast cancer patient-derived xenografts. Clin Cancer Res. 2015;21(24):5588–5600.
   PubMed Web of Science ®Google Scholar
• Femel J, Huijbers EJM, Saupe F, et al. Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer. Oncotarget. 2014;5(23):12418–12427.
   PubMedGoogle Scholar
• Han Z, Zhou Z, Shi X, et al. EDB fibronectin specific peptide for prostate cancer targeting. Bioconjug Chem. 2015;26(5):830–838.
   PubMed Web of Science ®Google Scholar
• Menrad A, Menssen HD. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets. 2005;9(3):491–500.
   PubMed Web of Science ®Google Scholar
• Chen H, Chen L, Sun L, et al. A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer. Gastric Cancer. 2011;14(4):339–352.
   PubMed Web of Science ®Google Scholar